Neuronetics Expects Q4 Revenue To Increase 86%; Stock Up

Neuronetics reported strong preliminary results for Q4 and FY2025, with preliminary Q4 revenue of $41.8M (up 86% reported, +23% on an adjusted pro forma basis) and full-year revenue of $149.2M (up 99% reported, +15% pro forma). NeuroStar system revenue rose to $18.3M (from $3.8M year‑ago) and clinic revenue to $23.5M (from $4.4M), with 49 NeuroStar systems shipped in Q4; the company ended 2025 with $34.1M in cash and generated positive operating cash flow in the quarter. Management plans to release final Q4 results on March 17, 2026 — a set of preliminary metrics that have already driven a strong premarket stock move and materially improve the company's near-term fundamentals.

Analysis

Market structure: Neuronetics (STIM) is a direct winner — Q4 pro forma growth of +23% YoY and 49 systems shipped implies rising installed base and recurring-treatment revenue (Q4 device revenue $18.3M, clinic revenue $23.5M). Competing TMS/neurostimulation vendors face pricing and share pressure as NeuroStar scales; clinics and service providers capturing recurring session margins also benefit. Macro cross-asset impact is concentrated: STIM should show elevated equity volatility and option IV; negligible direct effects on FX, commodities or sovereign bonds beyond microcap repricing dynamics.

Risk assessment: Key tail risks are regulatory/reimbursement changes (CMS coverage shifts) and operational scaling failures (manufacturing, service capacity) that could flip positive operating cash flow to cash burn; current cash = $34.1M so runway sensitivity >12 months only if positive OCF continues. Near-term (days-weeks) risk = event-driven volatility around March 17 earnings; medium-term (quarters) risk = adoption and payer mix; long-term (years) risk = clinical adoption and label expansion. Hidden dependencies include clinic referrals, payer reimbursements and device uptime/service economics.

Trade implications: Tactical: favor idiosyncratic exposure to STIM not sector beta. Use small, staged positions: entry on pullback to $1.40–$1.60 or add on confirmed March 17 results showing shipment cadence acceleration (>60 systems/Q). Options: buy limited-risk call spreads around earnings (Mar/Jun 2026 $1.50–$3.00) size 0.5–1% notional. Consider dollar-neutral pair: long STIM vs short IHI (medical devices ETF) to isolate company upside, rebalance monthly.

Contrarian angles: Consensus focuses on headline 86% reported growth while adjusted pro forma is +23% Q4 and +15% FY — the move may be overdone given low liquidity and microcap risk. Historical parallels: device stocks often gap up on shipment beats then trade down if reimbursement or repeat-use metrics disappoint. Unintended risk: aggressive installation pushes could degrade clinic economics and reduce lifetime recurring revenue, reversing the thesis.

Key Decisions for Investors

• Establish a staged long position in STIM equal to 2–3% portfolio weight: initiate 0.5–1% now on weakness to $1.40–$1.60, add another 1–2% only if March 17, 2026 results confirm shipment growth (>60 systems/Q) and adjusted pro forma guidance raises FY26 estimates; set hard stop-loss at $1.00 (≈30% downside).
• Implement a limited-risk options trade sized 0.5–1% notional: buy Mar/Jun 2026 call spread (long $1.50 call, short $3.00 call) to play near-term momentum around March 17 earnings while capping premium outlay.
• Run a dollar-neutral pair trade: long STIM (as above) vs short ETF IHI (medical devices) sized 1:1 dollar exposure to isolate company-specific upside; rebalance monthly and cut the pair if STIM falls below $1.00 or IHI outperforms by >10% in 30 days.
• Monitor three KPIs in next 30–60 days before scaling: system shipments per quarter (>60 = add), adjusted pro forma revenue growth (>25% YoY guidance for FY26 = accelerate buys), and cash balance/headcount burn (cash < $20M or negative OCF quarter = reduce to zero).